MENU
PPH
ETF ticker: NASDAQ
PRICE
CHANGE
NET ASSETS

PPH stock forecast, quote, news & analysis

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index... Show more

Category: #Health
A.I.Advisor
published price charts
PPH
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for PPH with price predictions
Oct 21, 2026

PPH in upward trend: 10-day moving average broke above 50-day moving average on October 20, 2026

The 10-day moving average for PPH crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on PPH as a result. In 68 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.

The Moving Average Convergence Divergence (MACD) for PPH just turned positive on October 09, 2026. Looking at past instances where PPH's MACD turned positive, the stock continued to rise in 42 of 50 cases over the following month. The odds of a continued upward trend are 84%.

PPH moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +2.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where PPH advanced for three days, in 282 of 345 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

Bearish Trend Analysis

The 10-day RSI Indicator for PPH moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In 32 of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at 82%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PPH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

PPH broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for PPH entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), McKesson Corp (NYSE:MCK), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN).

Industry description

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

Market Cap

The average market capitalization across the VanEck Pharmaceutical ETF (PPH) ETF is 167.25B. The market cap for tickers in the group ranges from 2.21B to 1.13T. LLY holds the highest valuation in this group at 1.13T. The lowest valued company is PRGO at 2.21B.

High and low price notable news

The average weekly price growth across all stocks in the VanEck Pharmaceutical ETF (PPH) ETF was 6%. For the same ETF, the average monthly price growth was 14%, and the average quarterly price growth was 133%. VTRS experienced the highest price growth at 6%, while AXSM experienced the biggest fall at -4%.

Volume

The average weekly volume growth across all stocks in the VanEck Pharmaceutical ETF (PPH) ETF was -30%. For the same stocks of the ETF, the average monthly volume growth was -43% and the average quarterly volume growth was -41%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 56
P/E Growth Rating: 50
Price Growth Rating: 37
SMR Rating: 59
Profit Risk Rating: 55
Seasonality Score: 13 (-100 ... +100)
PPH in upward trend: 10-day moving average broke above 50-day moving average on October 20, 2026